kidneynewsservice request card

1
Classified Ads Index to Advertisers Industry Spotlight E isai (Tokyo), a maker of cancer and neurological therapies, is closer to gaining a proven new benefit for its renal cancer treatment, lenvatinib (Kisplyx), in Germany, where 15,000 people develop renal cell carcinoma (RCC) every year. e German Institute for Quality and Efficiency in Health Care (IQWiG) published conclusions that lenvatinib when delivered in combination with everolimus has additional benefits in patients with RCC. e results of the institute’s report were announced by Eisai on Jan. 4, 2017, and will be evaluated by Germany’s Federal Joint Committee. A final decision on whether to accept results from the IQWiG report is expected in March 2017. Eisai submitted phase 2 trial data of 153 people with advanced RCC who had progressed after one previous vascular endothelial growth factor (VEGF) therapy. Patients were randomized to either receive everolimus or lenvatinib monotherapy, or a combination of both. e results showed significant differences in efficacy between the combination treatment and everolimus therapy alone. When treated with lenvatinib in combination with everolimus, patients experienced a median progression-free survival of 14.6 months compared with 5.5 months for a group of 50 patients who received everolimus alone (p=0.0005). Median overall survival in the study population was 25.5 months in the lenvatinib plus everolimus group compared with 15.4 months in the everolimus group in two update analyses. e European Commission, as well as the FDA, granted mar- keting authorization in 2016 for lenvatinib in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma after one VEGF therapy. German approval pending for RCC combo therapy benefit Kidney News Classified Advertising Information Classified space is for advertising positions available, open faculty positions, course announcements, seminars, meetings and educational courses. Display Advertising Rates Ad Size 1x 3x Full Page $2,525 $2,345 1/2 Page $1,665 $1,485 1/3 Page $1,435 $1,375 1/4 Page $1,205 $1,090 1/6 Page $1,035 $1,025 Line Advertising Rates Closing Date & Cancellations: Copy must be received four weeks in advance of the month in which the ad is to appear. Cancellation requests must be made in written form by fax, e-mail or postal mail and will be honored for the earliest applicable issue. Contact: Rhonda Truitt [email protected] P: 443-512-8899 x. 106 F: 443-512-8909 ALL ADS MUST BE PREPAID Please contact for rate information Nephrology Board Review 400+ABIM Style Questions. Comprehensive coverage of topics typically asked in Nephrology boards. Excellent for fellows, those taking boards, senior nephrologists to refresh their knowledge. Review at your own pace in comfort of your home. Worth every penny. See demo questions. Buy at WWW.RENALPREP.COM. I wish to start/renew a FREE* subscription to Kidney News 7-digit number label (Required for change of name/address only) Name Address City State Zip Telephone Fax Email Address Signature Date Title/position Physician Researcher RN, CNN, NM, LPN, APN, PA Dialysis Center Director Administration Clinic Manager/Coordinator Social Work Other Specialty Area General Nephrology Transplantation Dialysis Laboratory Other Institution Hospital <100 beds Hospital 100-250 beds Hospital 251-500 beds Hospital > 500 beds Dialysis Center Clinical Lab Other Please Circle Degree: MD MD/PhD DO PhD MBA RN MS BS Other_________ Free Subscriber Service Request Card KidneyNews Return the completed form to: Bob Henkel, 1510 H Street NW, #800, Washington, DC 20005 or Fax: 202-403-3615 or Email: [email protected] February 2017 | ASN Kidney News | 19 Topics that impact kidney practice, research and policy. Kidney News Online, updated daily. Mount Sinai . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 3 Nephcentric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 2 OPKO Renal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pages 10-12

Upload: others

Post on 25-Nov-2021

1 views

Category:

Documents


0 download

TRANSCRIPT

Classified Ads

Index to Advertisers

Industry Spotlight

Eisai (Tokyo), a maker of cancer and neurological therapies, is closer to gaining a proven new benefi t for its renal cancer treatment, lenvatinib (Kisplyx), in Germany, where 15,000

people develop renal cell carcinoma (RCC) every year.Th e German Institute for Quality and Effi ciency in Health Care

(IQWiG) published conclusions that lenvatinib when delivered in combination with everolimus has additional benefi ts in patients with RCC. Th e results of the institute’s report were announced by Eisai on Jan. 4, 2017, and will be evaluated by Germany’s Federal Joint Committee. A fi nal decision on whether to accept results from the IQWiG report is expected in March 2017.

Eisai submitted phase 2 trial data of 153 people with advanced RCC who had progressed after one previous vascular endothelial growth factor (VEGF) therapy. Patients were randomized to either receive everolimus or lenvatinib monotherapy, or a combination of both. Th e results showed signifi cant diff erences in effi cacy between the combination treatment and everolimus therapy alone.

When treated with lenvatinib in combination with everolimus, patients experienced a median progression-free survival of 14.6 months compared with 5.5 months for a group of 50 patients who received everolimus alone (p=0.0005). Median overall survival in the study population was 25.5 months in the lenvatinib plus everolimus group compared with 15.4 months in the everolimus group in two update analyses.

Th e European Commission, as well as the FDA, granted mar-keting authorization in 2016 for lenvatinib in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma after one VEGF therapy.

German approval pending for RCC combo therapy benefi tPRINT ADVERTISING

THE EFFECTIVE WAY TO:

GROW YOUR WORKFORCE

INVEST IN YOUR FUTURE WITH FELLOWSHIPS

FURTHER YOUR EDUCATION WITH CME COURSES

PROMOTE AN UPCOMING CONFERENCE

These plus more opportunities available when you contact

Rhonda [email protected]

443-512-8899 x 106

Kidney News Classified Advertising Information

Classified space is for advertising positions available, open faculty positions, course announcements, seminars, meetings

and educational courses.

Display Advertising RatesAd Size 1x 3x

Full Page $2,525 $2,345

1/2 Page $1,665 $1,485

1/3 Page $1,435 $1,375

1/4 Page $1,205 $1,090

1/6 Page $1,035 $1,025

Line Advertising Rates

Closing Date & Cancellations:Copy must be received four weeks in advance of the month in which the ad is to appear. Cancellation requests must be made in written form by fax, e-mail or postal mail and will be honored for the earliest applicable issue.

Contact:Rhonda Truitt

[email protected]: 443-512-8899 x. 106 F: 443-512-8909

All Ads

Must be PrePAid

Please contact for rate information

BC/BE NEPHROLOGIST

Outstanding opportunity for full-time, BC/BE Nephrologist in a Single Specialty Practice. The physician will join six FT nephrologists and two non-physician providers in a well-established, physician-owned practice that began operation in 1980. The Nephrologist will work in an excellent, award-winning medical community and support patients in eight dialysis units. The compensation package is competitive with paid medical/dental benefits for physician and family, generous 401k plan, and paid malpractice insurance. There is a two year partnership track that includes a JV opportunity. A signing bonus is included in the first year salary. There will be time to enjoy Colorado with a four day work week, one call weekend per month and six weeks of annual vacation. Fort Collins is located in northern Colorado, an hour north of Denver. The city is 5000 feet above sea level and enjoys 300 days of sunshine and only 14.5 inches of precipitation a year. Fort Collins is home to Colorado State University and an outstanding public school system. Fort Collins is not in an underserved area. Send CVs to [email protected] or fax to 970-493-2682.

CHIEF, DIVISION OF NEPHROLOGYNewton-Wellesley Hospital (NWH), a community teaching hospital in suburban Boston and a member of the Partners HealthCare System, Inc. (founded by the Massachusetts General Hospital (MGH) and the Brigham and Women’s Hospital), seeks a clinical nephrologist who demonstrates excellence in patient care, teaching, and administration, to serve as Chief of the Division of Nephrology. This individual, who will practice nephrology at NWH while overseeing the division, will identify opportunities to grow and expand the division. NWH is home to a comprehensive Cancer Center and is developing a state-of-the-art noninvasive Cardiovascular Center, in collaboration with MGH. NWH is an affiliate of the Tufts University School of Medicine and has postgraduate training programs for both Harvard Medical School and Tufts University School of Medicine trainees. The candidate must be Board Certified in Nephrology and qualify for an academic appointment at the rank of clinical associate professor or clinical professor. Please send cover letter and CV to Lawrence S. Friedman, MD, Chair, Department of Medicine, Attn: Alison Sholock, Newton-Wellesley Hospital, 2014 Washington Street, Newton, MA 02462, FAX 617-243-6701, Email [email protected]. NWH is an equal employment opportunity employer.

Nephrology Board Review400+ABIM Style Questions. Comprehensive coverage of topics typically asked in Nephrology boards. Excellent for fellows, those taking boards, senior nephrologists to refresh their knowledge. Review at your own pace in comfort of your home. Worth every penny. See demo questions. Buy at WWW.RENALPREP.COM.

I wish to start/renew a FREE* subscription to Kidney News

7-digit number label (Required for change of name/address only)

Name

Address

City State Zip

Telephone Fax

Email Address

Signature Date

Title/position Physician Researcher RN, CNN, NM, LPN, APN, PA Dialysis Center Director Administration Clinic Manager/Coordinator Social Work Other

Specialty Area General Nephrology Transplantation Dialysis Laboratory Other

Institution Hospital <100 beds Hospital 100-250 beds Hospital 251-500 beds Hospital > 500 beds Dialysis Center Clinical Lab Other

Please Circle Degree: MD MD/PhD DO PhD MBA RN MS BS Other_________

Free Subscriber Service Request CardKidneyNews

Return the completed form to: Bob Henkel, 1510 H Street NW, #800, Washington, DC 20005 or Fax: 202-403-3615 or Email: [email protected]

February 2017 | ASN Kidney News | 19Be a part of something innovative, influential, and dynamic.

Be a part of ASN.

World-class publicationsASN members receive subscriptions to CJASN, JASN, and Kidney News, and online access to NephSAP.

Travel supportMany travel support opportunities are available to help ASN members attend Kidney Week.

Live meeting discountsEnjoy reduced rates on ASN’s live educational programs, including Kidney Week and BRCU.

Distance learning discountsASN members receive discounts on distance learning, and can access cutting-edge resources anywhere.

Grant eligibilityThe ASN Foundation provides grant support to members at various stages in their careers.

Career resourcesWhether you’re searching for your first job or an advanced position, the Career Center has the resources you need.

To learn more and join or renew today, go to www.asn-online.org/membership.

ASN members enjoy an ever-expanding array of benefits, including:

Membership2016_FullTab.indd 1 12/28/2016 12:08:27 PM

Topics that impact kidney practice, research and policy. Kidney News Online, updated daily.

Mount Sinai . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 3Nephcentric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 2OPKO Renal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Pages 10-12